Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 7;10.1111/ajd.13313.
doi: 10.1111/ajd.13313. Online ahead of print.

COVID-19 and the Use of Immunomodulatory and Biologic Agents for Severe Cutaneous Disease: An Australian/New Zealand Consensus Statement

Affiliations
Free PMC article
Review

COVID-19 and the Use of Immunomodulatory and Biologic Agents for Severe Cutaneous Disease: An Australian/New Zealand Consensus Statement

Charlie Wang et al. Australas J Dermatol. .
Free PMC article

Abstract

Patients on immunomodulators, including biologic agents and new small molecular inhibitors, for cutaneous disease, represent a potentially vulnerable population during the COVID-19 pandemic. There is currently insufficient evidence to determine whether patients on systemic immunomodulators are at increased risk of developing COVID-19 disease or more likely to have severe disease. As such, clinicians need to assess the benefit-to-risk ratio on a case-by-case basis. In patients with suspected or confirmed COVID-19 disease, all immunomodulators used for skin diseases should be immediately withheld, with the possible exception of systemic corticosteroid therapy, which needs to be weaned. In patients who develop symptoms or signs of an upper respiratory tract infection, but COVID-19 is not yet confirmed, consider dose reduction or temporarily cessation for 1-2 weeks. In otherwise well patients, immunomodulators and biologics should be continued. In all patients, and their immediate close contacts, the importance of preventative measures to minimise human-to-human transmission cannot be overemphasised.

Keywords: COVID-19; Janus Kinase Inhibitors; biologic agents; biologics; ciclosporin; dermatolology; immunomodulators; methotrexate; systemic steroids.

Similar articles

See all similar articles

References

    1. Zhu N, Zhang D, Wang W et al A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020; 382: 727–33. - PMC - PubMed
    1. Doremalen N, Buschmaker T, Morris DH et al Aerosol and Surface Stability of SARS‐CoV‐2 as compared with SARS‐CoV‐1. N. Engl. J. Med. 2020; 382: 1564–7. - PMC - PubMed
    1. Young BE, Ong SW, Kalimuddin S et al Epidemiologic features and clinical course of patients infected with SARS‐CoV‐2 in Singapore. JAMA. 2020. 10.1001/jama.2020.3204. - DOI
    1. Bai Y, Yao L, Wei T et al Presumed Asymptomatic Carrier Transmission of COVID‐19. JAMA. 2020. 10.1001/jama.2020.2565. - DOI
    1. Rothe C, Schunk M, Sothmann P et al Transmission of 2019‐nCoV infection from an asymptomatic contact in Germany. N. Engl. J. Med. 2020; 382: 970–1. - PMC - PubMed

LinkOut - more resources

Feedback